Health

Strongest Adderall Alternative 2026: NeuroXen Report Maps OTC “Adderall Alternative” Search Behavior and a 5-Point Verification Framework

Pacific Palisades, California, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only and does not…

1 month ago

Strongest Phentermine Alternatives 2026: What OTC Options Actually Exist? Phen24 Consumer Search Analysis and 7-Point Verification Framework

Los Angeles, California, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only and isn't medical…

1 month ago

Liberation Bioindustries Announces New Roles for Founders

RICHMOND, Ind., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Liberation Bioindustries announces its co-founders have assumed new roles in the company;…

1 month ago

Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference

Two commercialized hematology products, Olverembatinib and Lisaftoclax, drive dual-engine growth with strong China market presenceNext-generation BTK protein degrader APG-3288 receives…

1 month ago

Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split

NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced…

1 month ago

New site in Lommel, Belgium: Aqua free successfully completes set-up phase with ISO 9001 certification

Lommel / Hamburg, 01/15/2026 – Aqua free, a leading provider of innovative drinking-water hygiene solutions, has successfully moved into its new,…

1 month ago

Inside information: Orion provides outlook for 2026 and estimates that the annual Nubeqa net sales recorded by Orion has potential to exceed EUR 1 billion in the future

January 14, 2026 01:30 ET  | Source: Orion Oyj ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION 14 JANUARY 2026 at…

1 month ago

New data reinforces Ipsens commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

14 abstracts will be presented across a range of neurological conditions including post‑stroke spasticity, cervical dystonia, blepharospasm and other movement…

1 month ago

HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet

— First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET…

1 month ago

Boehringer Ingelheim advances potential first-in-class IL-11 inhibitor to Phase II Clinical Research in Idiopathic Pulmonary Fibrosis

Not intended for US and UK audiences BI 765423 has been developed to target IL-11, a key driver of fibrosis…

1 month ago